SGL5213
SGL5213 is a low-absorbable, orally active dual inhibitor of human SGLT1 and SGLT2 (IC50 = 29 nM and 20 nM, respectively) . It is a research compound for studying sodium-glucose cotransporter pharmacology and has been investigated in preclinical models for type 2 diabetes management.
Product Specifications
CAS Number
1240305-17-2
Field of Research
Pharmacology & Drug Discovery
Smiles
O (C) C1=C (C=C (CC2=CC=C (/C=C/C (C (NC (C (NCCN (C) C) =O) (C) C) =O) (C) C) C=C2) C (C (C) C) =C1) [C@@H]3O[C@H] (CO) [C@@H] (O) [C@H] (O) [C@H]3O
Molecular Formula
C37H55N3O8
Molecular Weight
669.85
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb1641171-01 50 µg
High affinity immunoglobulin epsilon receptor subunit beta
Sign In for Pricing
View Details orb1641171-02 100 µg
High affinity immunoglobulin epsilon receptor subunit beta
Sign In for Pricing
View Details orb1641171-03 1 mg
High affinity immunoglobulin epsilon receptor subunit beta
Sign In for Pricing
View Details 
MBS1582134-01 50 Tests
Feline IgA, kappa Isotype Control antibody (HyHEL-10), PE
Sign In for Pricing
View Details MBS1582134-02 100 Tests
Feline IgA, kappa Isotype Control antibody (HyHEL-10), PE
Sign In for Pricing
View Details MBS1582134-03 5x 100 Tests
Feline IgA, kappa Isotype Control antibody (HyHEL-10), PE
Sign In for Pricing
View Details